SCHEMBL376440

SCHEMBL376440

COC(=O)c1ccn2ccnc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.48
KDM4E B2RXH2 4/20 0.46
KDM4C Q9H3R0 2/20 0.46
KDM6B O15054 1/20 0.46
KDM5C P41229 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
KDM3A Q9Y4C1 1/20 0.46
ALOX15 P16050 2/20 0.44
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
PIK3C3 Q8NEB9 1/20 0.43
NAMPT P43490 2/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
XDH P47989 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29450856 0.86 JMJD6 (0.38) JMJD6KDM4EKDM4CKDM6BKDM5C
SCHEMBL556235 0.83 JMJD6 (0.51) JMJD6KDM4EHTTCA12CA1
SCHEMBL28410809 0.82 NAMPT (0.60) SMN1; SMN2NAMPT
SCHEMBL15175942 0.82 MEN1 (0.43) SMN1; SMN2PIK3C3NAMPTSSTR4HSD11B1
SCHEMBL10138744 0.81 NTRK1 (0.48) PIK3C3NAMPTSSTR4HSD11B1MAPT
SCHEMBL600495 0.81 NAMPT (0.37) SMN1; SMN2PIK3C3NAMPTSSTR4HSD11B1
SCHEMBL15176490 0.81 NAMPT (0.47) PIK3C3NAMPTSSTR4HSD11B1
SCHEMBL3322287 0.80 NAMPT (0.50) PIK3C3NAMPTSSTR4MAPT
SCHEMBL557414 0.80 KDM4C (0.44) JMJD6KDM4EKDM4CKDM6BKDM5C
Hydrochloric Acid SCHEMBL1427773 0.79 NAMPT (0.37) SMN1; SMN2PIK3C3NAMPTSSTR4HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases ONCO3R THERAPEUTICS BV (BE) 2025-08-19 US disclosed
CN-115335043-B PGDH inhibitors and methods of making and using the same 迈欧伏特治疗公司 2025-03-28 CN disclosed
CN-113924146-B Novel compounds and pharmaceutical compositions thereof for the treatment of diseases 加拉帕戈斯股份有限公司 2024-12-10 CN disclosed
US-20240374579-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING EPIRIUM BIO INC. 2024-11-14 US disclosed
US-20240262820-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING MYOFORTE THERAPEUTICS, INC. 2024-08-08 US disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 EP disclosed
EP-3976189-B1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF DISEASES GALAPAGOS NV (BE) 2024-07-03 EP disclosed
CN-118201926-A Bicyclic PGDH inhibitors and methods of making and using the same 埃皮里姆生物股份有限公司 2024-06-14 CN disclosed
US-7297698-B2 N-phenyl-(2R,5S) dimethylpiperazine derivative ASTELLAS PHARMA INC. (JP) 2007-11-20 US disclosed
EP-1813613-A1 NOVEL FUSED IMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-01 EP disclosed
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative ASTELLAS PHARMA INC. (JP) 2005-11-24 US disclosed
EP-1557411-A1 N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2005-07-27 EP disclosed
EP-1235827-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2002-09-04 EP disclosed
WO-2001038326-A2 IMIDAZO-PYRIDINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 2001-05-31 WO disclosed
US-5137896-A Useful in treatment of gastrointestinal and psychic disorder; analgesic, antiemetic and antiulcer agent JANSSEN PHARMACEUTICA N.V. (BE) 1992-08-11 US disclosed
US-5057525-A Stimulators of gastrointestinal motility JANSSEN PHARMACEUTICA N.V. (BE) 1991-10-15 US disclosed
US-4962115-A Stimulate motility of gastrointestinal system JANSSEN PHARMACEUTICA N.V. (BE) 1990-10-09 US disclosed
EP-0076530-B1 NOVEL N-(3-HYDROXY-4-PIPERIDINYL)BENZAMIDE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 1985-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261303-A1 N-phenyl-(2r,5s) dimethylpiperadine derivative BPHL, QDPR, SRD5A2 JMJD6 943/4885KDM4E 299/4885KDM4C 205/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 JMJD6 864/4885KDM4E 2348/4885KDM4C 2166/4885
US-20240262820-A1 PGDH INHIBITORS AND METHODS OF MAKING AND USING HPGD, HPGDS, PTGS1 JMJD6 1826/4885KDM4E 3885/4885KDM4C 4347/4885
US-12391679-B2 Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases IL5, IL15, IL1A JMJD6 658/4885KDM4E 3302/4885KDM4C 1037/4885
US-20240374579-A1 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING HPGD, HPGDS, GCDH JMJD6 1956/4885KDM4E 4078/4885KDM4C 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.